Business Context and Reporting Period
Company: Oric Pharmaceuticals, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: March 31, 2026
Reporting Period: Event date March 31, 2026
The Company is a biopharmaceutical firm focused on developing novel therapies. This filing reports a specific corporate event regarding its clinical development program rather than a standard financial reporting period.
Key Financial Metrics
This Form 8-K filing does not contain financial statements, revenue figures, profit data, cash flow information, margin analysis, debt levels, or liquidity metrics. The document is strictly an event report regarding clinical trial updates.
Material Changes
Clinical Development Update: The Company presented a program update for rinzimetostat (ORIC-944) on March 31, 2026. The update specifically covered recently announced dose optimization data derived from the Company's Phase 1b trial.
Guidance, Outlook, and Management Commentary
- Management Commentary: The filing references a presentation (Exhibit 99.1) containing the dose optimization data for rinzimetostat. No specific forward-looking guidance, financial outlook, or risk factors are detailed within the text of this 8-K.
- Unusual Items: None reported in this filing.
Important Facts for Investor Verification
- Verify the specific dose optimization data for rinzimetostat (ORIC-944) by reviewing the attached presentation (Exhibit 99.1).
- Confirm the status and timeline of the Phase 1b trial for rinzimetostat.
- Review subsequent filings (e.g., 10-Q or 10-K) for financial impacts related to the clinical program.